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FACS22q11 deletion syndrome (22q11DS) is characterised by aberrant development of the pharyngeal apparatus
and the heart with haploinsufﬁciency of the transcription factor TBX1 being considered the major underlying
cause of the disease. Tbx1mutations in mouse phenocopy the disorder. In order to identify the transcriptional
dysregulation in Tbx1-expressing lineages we optimised ﬂuorescent-activated cell sorting of β-galactosidase
expressing cells (FACS-Gal) to compare the expression proﬁle of Df1/Tbx1lacZ (effectively Tbx1 null) and Tbx1
heterozygous cells isolated from mouse embryos. Hes1, a major effector of Notch signalling, was identiﬁed as
downregulated in Tbx1−/−mutants. Hes1mutant mice exhibited a partially penetrant range of 22q11DS-like
defects including pharyngeal arch artery (PAA), outﬂow tract, craniofacial and thymic abnormalities. Similar to
Tbx1 mice, conditional mutagenesis revealed that Hes1 expression in embryonic pharyngeal ectoderm
contributes to thymus and pharyngeal arch artery development. These results suggest that Hes1 acts
downstream of Tbx1 in the morphogenesis of pharyngeal-derived structures.ler).
he work.
-NC-ND license.© 2010 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
22q11 deletion syndrome (22q11DS) has an incidence of approx-
imately 1 in 4000 live births and classically comprises malformations
of the cardiovascular system, thymus gland, parathyroid gland and
craniofacial structures (Scambler, 2000). Haploinsufﬁciency of the
transcription factor TBX1 is considered to be the major underlying
cause of the disorder. While the penetrance and expression of the
deletion phenotype is very varied the cardinal features can be reca-
pitulated by TBX1 mutations in humans (Paylor et al., 2006; Stoller
and Epstein, 2005; Yagi et al., 2003; Zweier et al., 2007), mouse
(Jerome and Papaioannou, 2001; Lindsay et al., 2001; Merscher et al.,
2001), and zebraﬁsh (Piotrowski et al., 2003; Piotrowski and
Nusslein-Volhard, 2000). In order to understand the role of Tbx1 in
development efforts have been made to identify Tbx1 target genes
using “candidate gene” or transcriptomics approaches.
Our previous work has examined the downstream transcriptional
events of loss of Tbx1 in dissected pharyngeal tissues (Ivins et al., 2005;
Prescott et al., 2005). Several genes were identiﬁed and validated as
differentially expressed in Tbx1mutants. In particular we were able toshowadysregulation of genes in the retinoic acidmetabolismpathway
that are likely to contribute to the phenotype (Ivins et al., 2005;
Roberts et al., 2006). However, in these experiments the dissection
includes cell types that do not express Tbx1 and thus will either dilute
some tissue speciﬁc expression changes, or add noisewhere tissue loss
leads to a secondary expression change. We therefore aimed to repeat
our analysis using only cells actively expressing from the Tbx1
promoter. One of the Tbx1 null alleles was created with a knock in of
ß-galactosidase (Lindsay et al., 2001). We investigated whether a
ﬂuorogenic substrate for ß-galactosidase could be used to isolate Tbx1
expressing cells, ﬁrstly to further our target identiﬁcation program,
and secondly to demonstrate the general utility of this procedure in
light of the thousands of such knock-ins available via the mouse gene
trap program. FACS-Gal has been used previously on cultured cells
(Laugwitz et al., 2005) but involves preparative procedures that could
introduce noise into microarray analyses, and reduce cell viability
especiallywhen using early embryos.We therefore examinedwhether
the FACS-Gal procedure could produce good quality microarray data
from the material available from mid gestation embryos.
We utilized the Tbx1+/lacZ×Df1/+ cross to obtain Tbx1 null mu-
tants to ensure equivalent ﬂuorescence intensity from the Tbx1lacZ
allele in both genotypes. Df1 is a heterozygous deletion of 20 genes
including Tbx1 (Lindsay et al., 2001), thus the hemizygously deleted
Df1 genes could be used as internal controls to assess the quality of the
Fig. 1. CMFDG labelling and analysis of Tbx1LacZ cell enrichment. Example of CMFDG
labelling of an E9.5 Df1/Tbx1lacZ embryo separated from the rest of the litter by
phenotype. X-gal staining represents expression of the Tbx1lacZ allele. This labelling
procedure is also carried out on the Tbx1+/lacZ;Df1/+;wt pool of embryos. RT-PCR
analysis indicates that the wild type Tbx1 allele is present only in the FDG-positive cell
population containing Df1/+ and Tbx1+/lacZ cells. The Tbx1LacZ allele is only present in
FDG-positive cell populations and represents Df1/Tbx1lacZ and Tbx1+/lacZ cells.
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haploinsufﬁcient effect on gene expression, but Tbx1+/lacZ and Df1/+
embryos have indistinguishable phenotypes and Df1/Tbx1lacZ
embryos have exactly the same phenotype as Tbx1lacZ/lacZ mutants
(Lindsay et al., 2001) supporting their use as true Tbx1 nulls. Since we
were speciﬁcally interested in changes due to loss of Tbx1within cells
normally expressing that gene, validation by in situ hybridisation was
conducted using Tbx1lacZ/lacZ mutants.
The quality of the microarray data was tested by analysing the
down regulation of genes in ciswith Tbx1 and reduced to hemizygosity
in the Df1 deletion (Lindsay et al., 1999), and by validating selected
genes by RT-PCR in an independent sample. We selected the Hes1
transcription factor, an effector of Notch signalling for further analysis.
Hes+/− and Hes1−/− mouse embryos displayed a partially penetrant
phenotype including pharyngeal arch artery (PAA) hypo/aplasia, out-
ﬂow tract (OFT) misalignment, thymic agenesis and cleft palate —
defects seen in 22q11DS and Tbx1 null embryos. Conditional muta-
genesis indicated that lack of Hes1 expression in the neural crest had
no signiﬁcant effect on great vessel development and a mild effect on
thymic development. Concurrent ablation of Hes1 expression in
pharyngeal ectoderm and neural crest recapitulated much of the
thymic phenotype of constitutive nulls, as well as yielding a small
proportion of embryos with great vessel defects.
Results
FACS-Gal enrichment of Tbx1-expressing cells
In order to identify and enrich for Tbx1 targets we performed a
microarray comparing the gene expression proﬁle of Tbx1-expressing
cells from embryonic day 9.5 (E9.5) Tbx1+/lacZ and Df1/Tbx1lacZ (Tbx1-
null) embryos. Whole embryos were dissociated at E9.5, a stage at
which Tbx1 expression is mainly restricted to the pharyngeal region,
as recapitulated by the β-galactosidase reporter (Figs. 1, 2A–C). The
Tbx1lacZ allele was generated by inserting a lacZ construct into exon 5
of Tbx1, which encodes part of the DNA-binding domain (Lindsay
et al., 2001). Real-time PCR analysis has demonstrated that this
allele represents a true null allele (Zhang and Baldini, 2008). The
Tbx1lacZ allele was labelled using the ﬂuorogenic substrate, 5-
chloromethylﬂuorescein di-β-D-galactopyranoside (CMFDG) to com-
pare nulls with heterozygous embryos. E9.5 embryos were col-
lected and Df1/Tbx1lacZ embryos were separated by phenotype from
the Tbx1+/lacZ;Df1/+;wild type embryo pool for subsequent dissoci-
ation into a single cell suspension. After staining with the ﬂuorescent
substrate, CMFDG, cells were collected based on ﬂuorescent intensity
(above background) and cell viability (Fig. 1). FACS-Gal enrichment
yielded an average number of 600 cells per E9.5 embryo. Tbx1 driven
lacZ expression was observed in pharyngeal endoderm, ectoderm and
core mesoderm at this stage (Figs. 2A–C). Enrichment for Tbx1
expressing cells was examined by RT-PCR using primers that detected
only the wild type transcript, and primers that detected the IRES-lacZ.
The IRES-lacZ could be detected in FACS-Gal ﬂuorescent cell popula-
tions, but the wild type Tbx1 transcript could only be detected in the
heterozygote ﬂuorescent population demonstrating we had captured
the cells of interest (Fig. 1).
Microarray experiments were then carried out using Affymetrix
mouse MOE430 v2.0 arrays consisting of over 34000 well char-
acterised mouse genes. Analysis of the microarray experiments was
conducted using Genespring v4.2.1. Microarray experiments were
carried out using RNA extracted from 3 pools of Df1/Tbx1lacZ cells and
3 pools of Tbx1+/lacZ cells. The three pools were sorted from inde-
pendent groups of embryos to provide biological replication. Each
pool of cells was obtained from a group of at least 8 E9.5 embryos
(ranging in somite number from 17 s to 25 s). Pools of cells were used
tominimise variation due to staging differences. (The average number
of cells obtained per embryo was 535 cells per Df1/Tbx1lacZ embryoand 646 cells per Tbx1+/lacZ embryo.) Due to the limited number of
cells obtained, PCR ampliﬁcation was used to generate sufﬁcient RNA
for microarray analysis.
To assess the sensitivity of the approach formicroarraywe examined
the expression levels of genes reduced to hemizygosity in this cross. It
has been shown previously that the Df1 genes are decreased to
approximately 50% of wild type expression levels in Df1/+ hetero-
zygotes and they do not exhibit dosage compensation (Prescott et al.,
2005). Seventeen of 20 Df1 genes represented on the array were
expressed above threshold levels, and 16 of these 17 were down
regulated to an average of 0.611±0.096 (mean±SD) in Df1/Tbx1lacZ
arrays compared to Tbx1+/lacZ arrays (Table 1) indicating the sensitivity
of the experiment in detecting downregulated genes. The one of 17
Fig. 2. Expression of Hes1 in wild type and Tbx1−/− embryos. (A–C) Tbx1LacZ expression at E9.5. (A) Whole embryo, (B) coronal section and (C) transverse section of Tbx1+/LacZ
embryo. (D) Transverse section illustrating Hes1 expression at E9.5 by in situ hybridisation. (E–H) Whole mount in situ hybridisation (E–F) and corresponding transverse sections
(G–H) showing Hes1 expression is diminished in Tbx1−/−−/− embryos. a indicates arch; ov, otic vesicle. (I) Overlapping expression of Hes1 and Tbx1 as detected by
immunoﬂuorescence staining of transverse cryosections of wild type E8.5 embryos. Pharyngeal mesenchyme is indicated by a black arrow, endoderm by a white arrowhead,
mesoderm with a red arrowhead and ectoderm with a yellow arrowhead.
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described artifact secondary to the fact that this gene is at the Df1
deletion breakpoint (Ivins et al., 2005; Prescott et al., 2005).Table 1
Df1 genes analysed by microarray.
Gene Relative expression in Df1/Tbx1lacZ vs. Tbx1+/lacZ cells
Dgcr6 0.517±0.068
Zdhhc8 0.663±0.140
Ranbp1 0.598±0.095
Htf9c 0.549±0.104
D16h22s680e 0.563±0.267
Arvcf 0.490±0.165
Comt 0.601±0.118
Txnrd2 0.531±0.054
Septin 5 0.568±0.167
Ufd1l 0.459±0.091
Slc25a1 0.639±0.097
Cdc45l 0.694±0.206
Prodh 0.632±0.205
Dgcr8 0.807±0.153
Cldn5a 0.752±0.478
Gnb1la 0.706±0.325
Vpreb2 (L) 0.749±0.704
Rtn4r (L) 0.977±0.631
Tbx1 (L) 0.324±0.344
Es2el 1.459±0.238
L indicates low signal strength.
a These genes did not pass the ﬁltering and statistical analysis applied.In order to identify non-Df1 deletion genes which were down-
regulated in Df1/Tbx1lacZ cells, we chose a statistical ﬁlter which
selected the majority (14/16) of down regulated Df1 genes as having
signiﬁcantly reduced expression. This ﬁlter was downregulated to at
least 0.83 in 5 out of 6 Df1/Tbx1lacZ arrays compared to Tbx1+/lacZ
arrays, with pb0.05 using the Benjamini and Hochberg false discovery
rate correction. This resulted in a total of 1553unique sequenceswhich
were downregulated at least to the same degree as most Df1 genes
(Supplementary Table 1). The full dataset is available at ArrayExpress,
accession E-MEXP-2096.Validation of downregulated genes by qRT-PCR
Validation focused on downregulated genes because Tbx1 has been
demonstrated to be a transcriptional activator (Ataliotis et al., 2005;
Stoller and Epstein, 2005; Xu et al., 2004). Quantitative, real-time
PCR (qRT-PCR) was carried out to conﬁrm gene expression changes
using RNA ampliﬁed from an independent pool of Df1/Tbx1lacZ and
Tbx1+/lacZ cells collected by FACS from at least 10 E9.5 Df1/Tbx1lacZ
embryos and Tbx1+/lacZ embryos.
Genes were selected for independent validation by qRT-PCR based
on their expression pattern, knownor potential function in pharyngeal
or heart development, and signiﬁcant downregulation in the micro-
array experiments. Genes were also chosen based on their previous
identiﬁcation in other Tbx1 microarrays. Altogether, 30 genes down-
regulated in the absence of Tbx1were analysed by qRT-PCR; 18 (60%)
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12 genes showed no appreciable changes in expression (Table 2).
The most strikingly altered gene was Nkx2.6, whose expression
was completely abolished in Tbx1-null cells by qRT-PCR (Table 2).
Other genes which were downregulated greater than 3-fold were
Notch3 and Hes1, members of the Notch signalling pathway, Smad7,
required for heart development (Chen et al., 2009), and Cxcl4 and
Cdh1 whose role in pharyngeal or heart development have yet to be
characterised. Downregulation of a number of genes with a known
function in the pharyngeal apparatus or the heart (Sema3c, Isl1, Tbx18,
Bmpr1a,Dsg2 andGsk3β) were also validated by qRT-PCRwith Sema3c
exhibiting the greatest downregulation, to 0.360±0.170, in Tbx1-null
cells. The remaining validated genes (Crb3, Plek, Slit2, Lztﬂ1, Tle4 and
Daam1) represent additional, novel factors which have not previously
been shown to be involved in development of the pharyngeal system
and its derivatives.
To demonstrate the utility of the FACS-Gal approach in identifying
genes potentially contributing to Tbx1 loss of function phenotypes, we
chose Hes1 for further functional analysis. Targeted mutants were
already available, and other Notch pathway genes have previously
been implicated in cardiovascular morphogenesis as discussed below.
Hes1 is downregulated in the pharyngeal apparatus of Tbx1 null embryos
In situ hybridization revealed that Hes1 is expressed in the
pharyngeal region at E9.5 (Figs. 2D, E, G) and that this expression isTable 2
Genes validated by qRT-PCR.
Gene Average relative expression
in Df1/Tbx1lacZ cells
vs. Tbx1+/lacZ cells (±SD)
Signiﬁcance
(*pb0.05, **pb0.01)
Reason for
analysis
Nkx2.6 0±0 ** 1 #
Cxcl4 0.133±0.047 ** 3
Smad7 0.145±0.094 ** 2, 3
Cdh1 0.201±0.125 ** 3
Notch3 0.249±0.103 ** 2
Hes1 0.261±0.093 ** 2, 3 #
Crb3 0.386±0.058 ** 3 #
Sema3c 0.360±0.170 ** 1, 3
Pleckstrin 0.454±0.019 ** 3 ^
Slit2 0.529±0.125 ** 2
Lztﬂ1 0.562±0.153 ** 3
Isl1 0.643±0.153 * 1 #
Dsg2 0.656±0.020 ** 1, 3
Bmpr1a 0.712±0.116 ** 1
Tbx18 0.754±0.140 * 1, 3 #
Tle4 0.783±0.101 * 3
Daam1 0.797±0.152 * 2
Gsk3b 0.831±0.035 ** 1, 2
Dab2 0.721±0.185 # ^
Pitx1 0.814±0.134 2
FoxP1 1.025±0.349 1
Socs3 1.051±0.052 3
Lrr16 1.001±0.130 3
Tmeff1 1.032±0.270 3
Ephb2 1.264±0.312 1, 3
Tbx20 0.981±0.227 1
Pafah1b2 0.956±0.176 3
Dkk1 1.908±1.208 1 3 #
Cxcl12 1.048±0.086 2 3
Numb 1.493±0.879 3
Values represent average changes in gene expression of n=3 experiments (except for
Dsg2 where n=2).
Reasons for analysis:
1. Known role in pharyngeal/heart development.
2. Family members with a known role in pharyngeal/heart development in mice or
other species.
3. Stringently downregulated/multiple probes downregulated.
#Downregulated in Liao et al. (2008).
^Downregulated in Ivins et al. (2005).diminished, particularly in mesoderm and endoderm of Tbx1−/−
embryos of the same stage (Figs. 2F, H), consistent with diminished
Hes1 levels in FACS sorted Tbx1−/− cells. Expression of Tbx1 in pha-
ryngeal ectoderm at E8.5 is especially important for the great vessel
defects typically seen in 22q11DS (Randall et al., 2009; Zhang et al.,
2005). At the protein level, Hes1 is broadly expressed in pharyngeal
endoderm, ectoderm and pharyngeal mesenchyme (Fig. 2I) at this
stage. Dual staining reveals co-expression of Hes1 and Tbx1 in
pharyngeal ectoderm, endoderm and mesoderm (Fig. 2I). Together,
these data suggest a possible role forHes1 in themorphogenesis of the
pharyngeal apparatus.Hes1 mutant embryos have abnormalities of the pharyngeal arch arteries
A major feature of Tbx1 heterozygous animals and 22q11DS
patients is defective great vessel development secondary to abnormal
growth and remodelling of the 4th PAA (Lindsay et al., 2001). We
therefore assessed the growth and patency of Hes1 mutant PAAs at
E10.5 using ink injection and found a defect in 13/40 (32.5%)Hes1−/−
embryos analysed on an MF1 background (Table 3), including hypo/
aplasia of the 3rd, 4th (Fig. 3D) and 6th arch arteries (Fig. 3F), persis-
tent 1st and 2nd arch arteries (Fig. 3E and not shown), and aberrant
branching of the arch arteries (arrows and inset, Fig. 3E). We also
detected the same range of PAA defects in a smaller proportion of
heterozygous embryos (13/80, 16%) (Table 3, Figs. 3B, C), although
defects involved hypoplasia rather than aplasia.Hes1 mutants exhibit defects in vascular smooth muscle patterning
Defective PAA development can occur due to a failure of
endothelial tube formation or aberrant growth and remodelling. We
ﬁrst analysed formation of endothelial tubes using Endomucin, an
endothelial cell marker. Hes1mutant embryos with hypoplastic PAAs
or PAAs non-patent to ink still retained expression of Endomucin
surrounding the arteries even though they were very small at E10.5
(Fig. 4B). Thus, initial formation of the capillary tubes appears to
occur normally, although growth of the arteries is affected. The non-
endothelial component of the developing PAAs derives from the
surrounding neural crest (NC) which differentiates into smooth
muscle α-actin (α-SMA)-positive vascular smooth muscle (VSM)
surrounding the PAAs (Jiang et al., 2000; Li et al., 2000). Wild type
embryos at E11.5 showed strong expressionofα-SMAsurrounding the
3 rd, 4th and 6th PAAs (Fig. 3C). However, in Hes1−/−mutants which
exhibit hypoplastic PAAs, α-SMA staining is absent (PAA3, red arrow
in Fig. 4D) or diminished (PAA4, white arrow in Fig. 4D). These results
demonstrate that during PAA morphogenesis Hes1 is required for
normal VSM development.Table 3
Frequency of pharyngeal arch artery defects in E10.5 Hes1 mutants.
WT Hes1+/− Hes1−/−
Total embryos 77 80 40
Total normal 76 67 27
Total abnormal (%) 1 (1%) 13a (16%) 13a (32.5%)
Persistent 1st and/or 2nd PAA – 2 6
Hypo/aplastic 3rd PAA – – 1 (apl)
Hypo/aplastic 4th PAA 1 (hypo) 8 (hypo) 3 (hypo), 3 (apl)
Hypo/aplastic 6th PAA – – 1 (hypo)
Aberrant branching – 4 4
PAA, pharyngeal arch artery; hypo, hypoplastic; apl, aplastic.
Nb. Total WT embryos include additional WT non-littermates examined for the
presence of PAA defects.
a Signiﬁcantly different from WT (Fisher's exact test pb0.01).
Fig. 3. Intracardiac ink injection of E10.5 Hes1mutants. (A) In wild type embryos, bilateral pairs of caudal PAAs R3–R6 and L3–L6 are present at E10.5. (B) A proportion of Hes1+/−
mutants have hypoplasia of the fourth arch artery (arrow) and persistent ﬁrst and second arch arteries (C). Hes1−/− mutants also exhibit fourth arch artery aplasia (arrow in D),
persistent second arch arteries and aberrant branching of the arch arteries (arrow in E and inset) and sixth arch artery hypoplasia (arrow in F). L indicates left; R, right.
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Defective growth and remodelling of the PAAs produces later defects
of the great vessels. We examined E14.5 to E15.5 embryos on a pure
MF1, and a mixed MF1;C57Bl/6 (MF1;Bl6) background, by MRI,
histology and ink injection. A proportion ofHes1−/− embryos exhibited
cardiovascular defects (7/40, 17.5%, both genetic backgrounds; 4/23
(17%) MF1;Bl6 and 3/17 (17%) MF1) (Table 4, Fig. 5). We observed
defects in OFT alignment in 3/40 (8%) Hes1−/− homozygotes (1/23
(4%) MF1;Bl6 and 2/17 (12%) MF1) (Table 4, Figs. 5K, L) which were
accompanied by a ventricular septal defect (VSD) (Fig. 5H). Great vessel
defects (4/23 (17%) MF1;Bl6 and 1/17 (6%) MF1) included right-sided
aortic arch (RAA) (Figs. 5B, C), interruption of the aortic arch type B
(IAA-B) (Fig. 5C) and isolation of the right subclavian artery (I-RSA)
(Figs. 5D, F)whichbranchedoff thepulmonary trunk insteadof the right
common carotid. These defects represent aberrant development of the
4th PAA. Some embryos exhibited right-sided ductus arteriosus, a 6th
arch artery defect (Fig. 5B). The phenotype of theseHes1−/−mutants is
consistent with the earlier PAA defects present at E10.5.
Genetic background appeared to affect the penetrance of the Hes1
mutant phenotype. On an MF1 background, a proportion of Hes1−/−
mice exhibit neural tube defects and are also embryonic lethal prior to
E15.5 resulting in lower than expected numbers of Hes1−/− mutants
according to the predicted Mendelian ratios. However, on a mixed
background, no neurulation defects were identiﬁed and all genotypes
were present at the expected ratios (Supplementary Table 2). This
suggests that the proportion of MF1 Hes1−/− homozygotes with a
heart defect could be higher if investigated earlier. At E11.5, we noted
that a number of Hes1−/− embryos on an MF1 background exhibit
body hemorrhage and the yolk sac of these embryos appear to lack
large vitelline vessels (Supplementary Fig. 1), suggesting the earlier
lethality is due to a more serious defect in cardiovascular develop-ment. Thus, themixedMF1;Bl6 background appears to allow Hes1−/−
embryos to survive at least until E15.5.
In contrast to the PAAdefects detected inHes1+/− embryos at E10.5,
no great vessel abnormalities were found in Hes1+/− heterozygotes at
E15.5 (Table 4) indicating that these defectsmay largely recover later in
development. Tbx1 heterozygotes display a similar background depen-
dent rescue of PAA malformations as embryogenesis proceeds (Taddei
et al., 2001). However, one MF1;Bl6 Hes1+/− embryo was slightly
growth delayed in comparison to its littermates and had a cleft palate,
and another MF1 Hes1+/− embryo had dextroposition of the heart
(Table 4) indicating potential haploinsufﬁciency.
Fgf8 is required for PAA morphogenesis (Frank et al., 2002).
Furthermore, dominant negative interference of the Notch pathway in
the second heart ﬁeld gives rise to a defect in epithelial tomesenchymal
transition that, in ex vivo culture, can be rescued by Fgf8 (High et al.,
2009). Thus, down regulation of Fgf8 may contribute to both the arch
artery and outﬂow tract abnormalities observed inHes1 nulls. However,
no alteration of Fgf8, or Etv4, a readout for Fgf activity (Mao et al., 2009)
was detected at E8.5, while Fgf8, Fgf10 and Etv4 appeared unaffected at
E9.5 as well (Supplementary Fig. 2). qRT-PCR detected no quantitative
change in Etv4 or Etv5 expression at both stages (Supplementary Fig. 2).
MRI of Hes1 mutant embryos reveals additional
22q11DS-like malformations
One of the original descriptions of Hes1 null mutants commented
upon lack of thymus gland development (Tomita et al., 1999). To
quantify this and survey the anatomy of mutants we used MRI of
E15.5 embryos on both a mixed MF1;C57Bl6 and pure MF1 back-
ground. We found highly penetrant thymic hypo/aplasia on both
backgrounds (Table 4, Fig. 5P). Of particular note is the presence
of cleft palate in 9/15 (60%) MF1 Hes1−/− embryos and 9/23, (39%)
Fig. 4. Hes1 mutants exhibit loss of vascular smooth muscle markers in the developing PAAs. (A, B) Immunoﬂuorescence on coronal E10.5 embryo sections for the endothelial
marker, Endomucin (Endo). Endo staining is present in wild type (A) and Hes1−/− embryos with aplastic/non-patent 4th PAAs (arrow in B). (C, D) Immunoﬂuorescence on coronal
E11.5 embryo sections for α-SMA. Strong α-SMA expression surrounding the 3 rd, 4th and 6th PAA in wild types (C) is lost in the hypo/aplastic left 3 rd and 4th PAA (red and white
arrows in D, respectively) of Hes1−/− mutant embryos. The contralateral vessels, which have formed in this embryo, have normal α-SMA staining.
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Tbx1−/− embryos of the same stage (Jerome and Papaioannou, 2001).Expression of other notch pathway genes is altered in FACS isolated
Tbx1-null cells
Hes1 is the main effector of Notch signalling and Notch pathway
genes have previously been implicated in cardiovascular development
(High and Epstein, 2008). We therefore analysed expression of
Notch pathway genes by qRT-PCR to investigate whether Hes1 may
be downregulated in Tbx1 mutants due to aberrant Notch signalling.
In Df1/Tbx1lacZ cells, the Notch receptors, Notch3 and Notch4 are
downregulated while Notch1 and Notch2 are upregulated. In addition,
the Notch ligand, Dll1 and DNA-binding transactivator, Rbpj are also
upregulated (Supplementary Fig. 3). These results could suggest that
Hes1may act downstream of Notch3 or Notch4. Upregulation of other
Notch pathway members could be due to functional compensation or
negative feedback from loss of Hes1. The incomplete penetrance of
pharyngeal-derived defects in Hes1 mutants suggest a possible func-
tional redundancy with other Hes-related genes, especially since
HeyL;Hey1 double mutants, but not single mutants, have heart defects
(Fischer et al., 2007). In addition, Hes1, Hey1 and Hey2 bind to
promoters of an overlapping set of genes (M. Gessler, personal
communication). In Tbx1-null cells,Hey1 expression is diminished butTable 4
22q11DS-like defects observed at E14.5–E15.5.
Strain Genotype n Total CV
defects
Great
vessel
defect
OFT
defect
Cleft
Palate
Thymic
hypo/aplasia
MF1 Hes1−/− 15 2 (13%) 1 9 (60%) 13 (87%)
Hes1+/− 15 1a (7%) 0 0 0 0
WT 2 0 0 0 0 0
MF1;C57Bl/6 Hes1−/− 23 5 (22%) 4 2 9 (39%) 23 (100%)
Hes1+/− 21 0 0 0 1 (5%) 0
WT 7 0 0 0 0 0
CV — cardiovascular, OFT — outﬂow tract, WT — wild type.
a Dextroposition of the heart.Hey2 is unchanged and HeyL is upregulated 3.4 fold (Supplementary
Fig. 3).
Hes1 is required in embryonic pharyngeal ectoderm for normal thymic
development
Conditional dominant negative interference of Notch signalling in
cardiac neural crest cell progenitors (using Pax3Cre and Wnt1Cre)
results in pulmonary stenosis and aortic arch patterning defects (High
et al., 2007). Thus, even though Tbx1 is not expressed in neural crest,
we investigated Hes1 requirements in these cells as the effect of loss
of Tbx1 on Hes1 expression might be indirect. We therefore crossed
Hes1+/−;Wnt1Cre mice to Hes1ﬂ/ﬂ mice using a conditional allele for
Hes1 (Kita et al., 2007), and assessed defects in pharyngeal structures.
Although it can only act as a surrogate for recombination at the Hes1
locus, the ROSAR26R reporter conﬁrmed strong Cre activity in neural
crest lineages within this cross (i.e. on the same genetic background
(Figs. 6A–C)). Thymic hypo/aplasia was observed in 3 of 21 Hes1ﬂ/−
embryos, 2 of 31 embryos hemizygous for Hes1 in neural crest only,
and in 10 of 26 (38%) Hes1ﬂ/−;Wnt1Cre embryos. Thus, complete loss
of Hes1 in neural crest increased the frequency of thymic hypoplasia;
however, there were no instances of thymic aplasia in these crosses.
Great vessel defects were not apparent in any embryos (Table 5). In
summary, there is not a major requirement for Hes1 in the neural
crest lineage although a contributory role in thymus developmentwas
detected.
Tbx1 is required in pharyngeal epithelia for normal great vessel
morphogenesis (Zhang et al., 2005). We have recently reﬁned this to a
requirement in pharyngeal ectoderm (Randall et al., 2009). Thus, to
investigate the requirement for Hes1 in ectoderm we used the
Ap2αCre driver which effects recombination in both ectoderm and
neural crest, the results being compared to the Wnt1Cre, neural crest
only, conditionals. The ROSAR26R reporter was used to assess recom-
bination within this cross and conﬁrmed strong Cre activity in the
embryonic surface ectoderm and neural crest lineages (Figs. 6D–F). 26
of 32 (81%) Hes1ﬂ/−;Ap2αCre as compared to 2 of 23 Hes1ﬂ/− (9%)
embryos exhibited thymic hypo/aplasia (Table 5, Figs. 6K–M). This
recapitulates much of the thymic malformation seen in the constitu-
tive nulls, (thymic aplasia was noted in seven cases). In two of 36 (6%)
Hes1ﬂ/−;Ap2αCre embryos we observed a great vessel defect. One
Fig. 5. 22q11DS-like defects in E15.5 Hes1−/−mutants. (A–D) Great vessel defects in E15.5 Hes1−/− embryos. (A) Normal wild type (wt) great vessel morphology. (B–D) Hes1−/−
(–/–) mutants with RAA and right-sided ductus arteriosus (B), IAA-B and RAA (C), and I-RSA (D). (E) In wt embryos, the right subclavian artery branches off the right common carotid.
(F) Hes1−/− mutant in which the right subclavian branches off the pulmonary trunk. (G–L) OFT defects and VSD in Hes1−/− mutants. (G, H) Transverse MRI scans. (I–L) Transverse
histological sections. (G) In wild type embryos the interventricular septum separates the right and left ventricles. (H) Hes1−/−mutants exhibit a VSD (dark staining represents blood).
(I, J) Consecutive transverse sections of a wild type embryo in which the pulmonary trunk arises from the right ventricle (I) and the aorta joins the left ventricle (J). (K, L) Consecutive
sections of a Hes1−/− embryo with double outlet right ventricle in which both the aorta and pulmonary trunk arise from the right ventricle. (M, N) Transverse MRI sections of the
palate at E15.5. (M) In wild type embryos the palatal shelves are fused. (N) Hes1−/−mutants exhibit cleft palate where the palatal shelves do not meet in the midline. (O, P) Transverse
MRI sections of the thymic lobes which are missing in Hes1−/− mutants (P). ao indicates aorta; aoa, aortic arch; da, ductus arteriosus; ivs, interventricular septum; lcc, left common
carotid; lsca, left subclavian artery; lv, left ventricle; ps, palatal shelf; pt, pulmonary trunk; rcc, right common carotid; rsca, right subclavian artery; rv, right ventricle; t, tongue; th,
thymic lobe; vsd, ventricular septal defect. Asterisks indicate missing segments.
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isolation of the right subclavian artery, abnormalities which occur due
to defective development of the 3rd and 4th PAA, respectively
(Figs. 6H, I). This frequency of defects does not fully reproduce that
seen in constitutive mutants suggesting a modifying effect of genetic
background or that great vessel morphogenesis requires Hes1
expression in additional tissues. In summary, ectodermal expression
of Hes1 makes a major contribution to thymus development and also
plays a role in PAA development. As Ap2αCre effects recombination in
both ectoderm and neural crest, a synergistic effect of crest ablation of
Hes1 in the absence of ectodermal expression cannot be ruled out.
Hes1 is required for normal cell proliferation in the pharyngeal ectoderm
Previous analyses have demonstrated impairment of cell cycle
progression in the pharyngeal endoderm and second heart ﬁeld, but
not the myocardium, of Hes1 mutants (Rochais et al., 2009). We
therefore asked whether pharyngeal ectoderm was similarly affected.
PAA and thymic development requires Tbx1 at stage E8.5 (Xu et al.,
2005). At this stage, we observed decreased proliferation in the
ectoderm — a reduction in the number of phospho-histone H3 posi-
tive cells (from 20 to 14%) in Hes1 nulls compared to wild type
controls (Fig. 7; pb0.02). There was also an increase in the number ofKi67 negative (quiescent) cells (from 6 to 9.6%), (Fig. 7; pb0.05).
There was no alteration in apoptosis in the pharyngeal ectoderm or
neural crest at E9.5 (assayed using a caspase3 antibody (not shown)).
The sections studied are from the same embryos used by Rochais et al.
(2009). Our results indicate that Hes1 is important for proliferation of
the pharyngeal ectoderm, which may in turn affect morphogenesis of
the thymus and PAAs. Altered proliferation is unlikely to be secondary
to decreased Fgf8 signalling at this stage, since expression of Fgf8 itself
and downstream readout of Fgf activity are not detectably altered
(Supplementary Fig. 2).
Discussion
Our studies demonstrate that FACS-Gal is a useful technique to
enhance the power of transcriptomics studies of murine embryo-
genesis. FACS-Gal can make use of the large existing repository of
β-galactosidase-trapped ES lines now encompassing approximately
33% of all mouse genes (http://www.genetrap.org/index.html).
Isolation of the expressing cells of interest will enrich for autonomous
effects and reduce noise from non-expressing tissues. Moreover, the
existence of Cre-reversible traps opens the way to within group com-
parisons of ﬂow-sorted cells, one pool having had expression restored
using a tamoxifen activated Cre enzyme.
Fig. 6. 22q11DS-like defects in E10.5 and E15.5 Hes1 conditional mutants. (A–F) ROSAR26R reporter crosses. (A–C) Hes1−/ﬂ;Wnt1Cre x ROSAR26R and (D–F) Hes1−/ﬂ;Ap2αCre x
ROSAR26R crosses following X-gal staining. (A) E9.5 whole mount image, (B) sagittal section of (A) showing strong recombination in the neural crest of ﬁrst and second pharyngeal
arches (black arrows), and (C) transverse section of (A) showing recombination in the neural crest cells at the second heart ﬁeld level (white arrow). (D) E9.5 whole mount image,
(E) sagittal section of (D) showing strong recombination in the neural crest and ectoderm of ﬁrst and second pharyngeal arches (black arrows) and (F) transverse section of (D)
showing recombination in the ectoderm (black arrow) and neural crest cells (white arrow). (G–I) Great vessel defects in E15.5 Hes1−/ﬂ;Ap2αCre embryos. (G) Normal Hes1+/ﬂ (wild
type) great vessel morphology. (H–I) Hes1−/ﬂ;Ap2αCre (Hes1 null in the ectoderm and neural crest) mutants with aberrant branching of the RCC (H) and I-RSA (I). (J) Intracardiac
ink injection of E10.5 Hes1−/ﬂ;Ap2αCre mutants displaying persistent second arch arteries (R2, L2) and unilateral third arch artery aplasia (arrow). (K–O) Thymic defects in
E15.5 Hes1−/ﬂ;Ap2αCre embryos. (K) Normal thymic lobe morphology in Hes1+/ﬂ (wild type) embryos. (L–M) Hypoplastic lobes (L) and a single, hypoplastic lobe (M) observed in
Hes1−/ﬂ;Ap2αCre mutants. (N–O) Transverse section of the thymic lobes in Hes1−/ﬂ;Ap2αCre embryos showing normal development (N) and aplasia (O). aoa indicates the aortic
arch; lcc, left common carotid; oft, outﬂow tract; rcc, right common carotid; rsca, right subclavian artery; rv, right ventricle; t, thymic lobe. Asterisks indicate missing or duplicated
segments.
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Tbx1-null and Tbx1-heterozygous cells and identiﬁed a list of potential
Tbx1 targets including Hes1. Recently, an independent microarray
screen also identiﬁed Hes1 as downregulated in dissected Tbx1−/−
caudal pharyngeal tissue (Liao et al., 2008). These experiments were
aimed at identifying dysregulated genes in the secondary heart ﬁeld,Table 5
22q11DS-like defects observed at E15.5 in the Hes1 conditional mutants.
Strain Genotype n Total CV
defects
Great
vessel
defect
OFT
defect
Thymic
hypo/aplasia
MF1;C57Bl/6 Hes1ﬂ/−;Wnt1Cre 26 0 0 0 10 (38.5%)
Hes1ﬂ/+;Wnt1Cre 31 0 0 0 2 (6.5%)
Hes1ﬂ/− 21 0 0 0 3 (14.3%)
Hes1ﬂ/+ (WT) 17 0 0 0 0
MF1;C57Bl/6 Hes1ﬂ/−;Ap2αCre 32 2 (6.25%) 2 0 26 (81.3%)
Hes1ﬂ/+;Ap2αCre 20 0 0 0 0
Hes1ﬂ/− 23 0 0 0 2 (8.7%)
Hes1ﬂ/+ (WT) 27 0 0 0 2 (7.4%)
CV — cardiovascular, OFT — outﬂow tract, WT — wild type.and were not restricted to Tbx1-expressing cells. Nevertheless there
were genes identiﬁed in common with those reported here. In
particular, Hes1 was downregulated 2.5 fold at E8.75. Four other genes
were downregulated by microarray and conﬁrmed by qRT-PCR in both
studies: Nkx2.6, Crb3, Isl1, and Dab2. Thus these ﬁve genes represent
excellent candidates to contribute to the phenotype caused by loss of
Tbx1. Nkx2.6was almost undetectable by qRT-PCR in the Tbx1−/− cells,
and missense mutation of the gene has been described in common
arterial trunk malformation in humans (Heathcote et al., 2005). Nkx2.6
is expressed transiently in themouse embryonic pharyngeal endoderm,
but Nkx2.6−/− mice are apparently normal (Tanaka et al., 2000).
However,Nkx2.5 expression expands intoNkx2.6 expression domains in
these mutants suggesting a regulatory compensation by Nkx2.5.
Consistent with this hypothesis, Nkx2.6−/−;Nkx2.5−/− embryos had
an abnormal, dilated pharynx with reduction in the numbers of
endodermal cells, phenotypes not observed in Nkx2.5−/− single
mutants (Tanaka et al., 2001). However, the Nkx2.6−/− mouse line is
no longer available to pursue the possibility of Tbx1:Nkx2.6 interaction.
We focused on Hes1 as a gene worth investigating for a possible
biological role in themorphogenesis of structures requiring Tbx1.Hes1
represents one of the main effectors of Notch signalling and has been
Fig. 7. Proliferation defect in Hes1 mutants. (A–B) Immunohistochemistry with anti-
phospho-Histone H3 (PH3) antibody in parafﬁn sections of E8.5 WT (A) and Hes1−/−
(B) embryos showing a decrease in PH3-positive cells within the surface ectoderm of
Hes1−/−mutants (arrowhead). (C–D) Immunohistochemistry with anti-Ki67 antibody
in sections of E8.5WT (C) andHes1−/− (D) embryos showing an increase in the number
of Ki67-negative cells in Hes1−/− embryos (arrowhead). (E) Graph comparing the
percentage of PH3 positive cells and Ki67 negative cells in the pharyngeal ectoderm of
WT embryos andHes1−/−mutants. A signiﬁcant decrease in PH3 positive cells (pb0.05)
and increase in Ki67 negative cells (pb0.05, Student's t-test) is observed in Hes1−/−
mutants.
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Hes1 is known to be involved in thymic morphogenesis (Tomita et al.,
1999) and recently, Hes1 has been shown to play a role in the devel-
opment of the outﬂow tract (Rochais et al., 2009). However, to date
there has been no published role for Hes1 in pharyngeal arch artery or
palate development. Numerous members of the Notch pathway
play important roles in cardiovascular development, including the
Notch ligand, Jag1 and the Notch target genes, Hey1, Hey2 and HeyL
(Donovan et al., 2002; Fischer et al., 2004, 2007; Gessler et al., 2002;
Kokubo et al., 2005, 2004; Li et al., 1997; Oda et al., 1997; Sakata et al.,
2002). These Notch pathway genes are known to be important for
processes such as arterial-venous differentiation and targeted Notch
pathway mutants exhibit heart defects including VSDs, atrioventric-
ular valve defects, tetralogy of Fallot and cardiomyopathy (Donovan
et al., 2002; Fischer et al., 2004, 2007; Gessler et al., 2002; Kokubo
et al., 2005, 2004; Sakata et al., 2002). Dominant negative repression
of Notch signalling within the neural crest (NC-DNMAML mutants)
causes a range of heart defects, predominantly pulmonary stenosis
and great vessel defects (High et al., 2007). SHF-speciﬁc inhibition of
Notch signalling (SHF-DNMAML mutants) also results in great vessel
defects as well as OFT alignment and septation defects (High et al.,
2009). However, Hes1 is the ﬁrst Notch effector mutant described ashaving PAA abnormalities. While it is possible that functional redun-
dancy among related Notch pathway members may explain this
inconsistency, our ﬁndings reveal that Hes1−/− mutants exhibit a
spectrum of PAA-derived malformations similar to those which occur
in DNMAML mutants (High et al., 2007) suggesting that Hes1 may
play a dose-dependent role in mediating the effects downstream of
Notch signalling in PAA development and remodelling. Hes-related
genes are expressed in overlapping domains with Hes1 within
pharyngeal tissues including the neural crest and pharyngeal
endoderm (High et al., 2007). This potential for redundancy may
provide an additional explanation for the partially penetrantHes1 null
phenotypewe observed. Indeed, we observed a 3.4 fold increase in the
level of HeyL expression in Tbx1−/− cells. Hey gene functional redun-
dancy could affect analysis of a genetic interaction between Tbx1 and
Hes1 in doubly heterozygous mice. It will therefore be interesting in
the future to determine whether DNMAML and Tbx1mutants show an
epistatic relationship during development.
The spectrum of PAA malformations in Hes1 mutants ranges from
persistence of the 1st and 2nd arch arteries to hypo/aplasia and
aberrant branching of the caudal PAAs. This phenotype is similar to NC
ablation phenotypes (Hutson and Kirby, 2007). Thymic and palatal
defects are also found in several neural crest gene mutants (Gritli-
Linde, 2007; Rodewald, 2008). Hes1+/− heterozygotes exhibit PAA
defects at E10.5 however, they exhibit hypoplasia and aberrant PAA
branching rather than aplasia. The relatively mild phenotype may
represent an intermediate defect in PAA patterning from which
embryos recover during development. This may help to explain why
the percentage of embryos with PAA defects has decreased at E15.5 in
Hes1−/− nulls and why no Hes1+/− heterozygotes appeared with
PAA-derived defects later in development. A similar reduction in PAA
derivative defects is seen in Tbx1 mice (Lindsay and Baldini, 2001).
Here, we show that Hes1 and Tbx1+/− mutants exhibit an over-
lapping phenotype, speciﬁcally 4th PAA hypo/aplasia, thymic hypo/
aplasia and cleft palate. In PAA development, Tbx1 is known to play a
non-cell autonomous role in controlling VSM differentiation (Calmont
et al., 2009; Lindsay and Baldini, 2001; Zhang et al., 2005). Similarly,
Hes1 mutants exhibit a defect in VSM patterning of the PAAs which
may be due to decreased NC contribution (Rochais et al., 2009) and/or
a failure of the NC to properly differentiate, suggesting that Hes1may
act downstream of Tbx1 to effect its role in PAA morphogenesis.
It is possible that Hes1 acts as an indirect target of Tbx1 through
downregulation of the Notch signalling pathway. In support of this
role, downregulation of Notch signallingwithin the NC causes a failure
of VSM differentiation and SHF-DNMAML mutants exhibit aberrant
CNC migration both leading to PAA defects (High et al., 2009, 2007).
Tbx1 is required within the pharyngeal ectoderm for PAA, thymus
and palate development (Randall et al., 2009). Tbx1 is not expressed in
the NC but we wanted to ascertain what role Hes1 played in this
tissue. We speciﬁcally ablated Hes1 within the NC using Wnt1Cre. No
great vessel defects were observed in these embryos, the only abnor-
malities involving thymus gland hypoplasia. We therefore used the
Ap2αCre driver and a conditional Hes1 allele to test Hes1 requirements
within the pharyngeal ectoderm. We observed a low frequency great
vessel defect, however thymic hypo/aplasia was prevalent in Ap2αCre
conditional Hes1 mutants, suggesting a non-cell autonomous role of
Hes1 to organogenesis similar to Tbx1 (Randall et al., 2009). It remains
to be determined what role, if any, Notch signalling plays within the
pharyngeal ectoderm. However, we surmise that expression of Hes1
in tissues other than ectoderm and neural crest will contribute to
cardiovascular morphogenesis because the pharyngeal ectoderm-
speciﬁc knockout of Hes1 did not recapitulate the spectrum and
frequency of defects seen in constitutive Hes1 nulls. In particular,
second heart ﬁeld and pharyngeal endoderm lineages may be impor-
tant in this regard. Disruption of Notch signalling within the SHF
causes OFT alignment and septation defects and great vessel abnor-
malities (among other cardiovascular malformations). These defects
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to a decrease in CNC migration through the pharyngeal arches (High
et al., 2009). Hes1 mutants exhibit reduced proliferation within the
SHF and show similar CNC migration defects (Rochais et al., 2009). It
will be interesting to determine whether SHF-speciﬁc Notch deletion
mutants also exhibit decreased proliferation of SHF progenitors and to
examine the SHF-speciﬁc role ofHes1 in OFTmorphogenesis. The SHF-
DNMAML mutants also had defective endothelial to mesenchymal
transition in endocardial cushion explant tissue (High et al., 2009).
Addition of exogenous Fgf8 to these cultures was sufﬁcient to rescue
the defect. As Fgf8 is also intimately involved in PAA morphogenesis
we examined Fgf8 and Fgf10 expression, together with Fgf activity as
determined by Etv4/Etv5 expression, in Hes1 null embryos, but no
abnormalities were observed.
Together, these data support a non-cell autonomous role for Hes1
in thymic and, to a lesser extent, PAA morphogenesis and adds to
recent data indicating the importance of the embryonic pharyngeal
ectoderm in this process. One possibility is that Hes1 regulates an
aspect of signalling from the pharyngeal ectoderm to the neural crest
or other mesenchymal cell types, as we have postulated for Gbx2
(Calmont et al., 2009). A second possibility is that the moderate
decrease in cell proliferation seen in pharyngeal ectoderm of Hes1−/−
embryos could result in a decrease in the number of the relevant
signalling cell lineages. Despite the comparatively restricted neural
crest conditional phenotype, a role for Hes1 in regulating differenti-
ation of the postmigratory NC cannot be excluded since the Ap2αCre
driver effects recombination in neural crest as well as ectoderm. Hes1
has previously been shown to play dual roles within the same tissue in
maintaining proliferation of stem cells and promoting differentiation
depending on the developmental stage (Ohtsuka et al., 2001). We
detected reduced proliferation in pharyngeal ectoderm of Hes1 null
embryos, but markers for progenitor differentiation are not available
for this tissue.
Hes1 has primarily been described as an effector of Notch
signalling, but there is evidence that Hes1 also acts independently of
Notch through signalling pathways including Shh and Vegf (de la
Pompa et al., 1997; Hashimoto et al., 2006; Ingram et al., 2007).
Furthermore, Tbx transcription factors have been shown to regulate
members of the Hes-related family in heart development (Rutenberg
et al., 2006). These results suggest that a conserved regulatory
pathway may exist between T-box transcription factors and members
of the Hes family. Tbx1 regulation of the Notch pathway has been
observed in the developing ear. However, in this situation, loss of Tbx1
results in some members of the Tbx1-dependent cell population
switching to a neurogenic fate, an event associated with activation of
the Delta-Notch pathway. It is not known whether this is a direct or
indirect regulation (Xu et al., 2007).
The decreased expression of Hes1 in the Tbx1LacZ expressing, Tbx1
null cells could be explained by several mechanisms (see Supple-
mentary Fig. 4), including direct transcriptional regulation. Transfec-
tion assays to date have so far failed to support direct action of Tbx1
on the Hes1 promoter (data not shown), thus the molecular basis of
the Hes1 regulation by Tbx1 remains to be elucidated. Since Tbx1
regulates cell proliferation, loss of Tbx1 could reduce the number of
Hes1 expressing cells, detected as reduced Hes1 transcript abundance
by FACS-GAL. As Hes1 is also involved in controlling cell proliferation,
this would result in overlap between the Hes1 and Tbx1 loss of func-
tion phenotypes in the absence of a direct regulatory relationship. A
third possibility is that Tbx1 directly or indirectly controls expression
of other Notch pathway genes (e.g. Notch3, which had reduced
expression in the FACS-Gal enriched Tbx1-null cells). In this model,
Hes1 would be indirectly downregulated as a consequence.
This work demonstrated the utility of FACS-Gal for identifying
genes dysregulated in embryonic models of human disease. Hes1 was
validated as downregulated in Tbx1 null embryos and shown to be
required for the normal formation of pharyngeal-derived structures.In particular, expression of Hes1 in embryonic pharyngeal ectoderm
was shown to be required for normal thymus development and
makes a contribution to pharyngeal arch artery morphogenesis. Thus,
Hes1 downregulation may contribute to the Tbx1 loss of function
phenotype.
Materials and methods
Mice
Tbx1+/lacZ and Df1/+ mice have been described previously and
were maintained on a C57BL/6 background (Lindsay et al., 1999,
2001). Hes1+/−mice (Ishibashi et al., 1995) were kindly provided by
Francois Guillemot, National Institute of Medical Research, UK and
maintained on a MF1 and CD1 background. Wnt1Cre mice (Danielian
et al., 1998) were kindly provided by Andrew Copp, Institute of Child
Health, University College London, London, UK and maintained on a
C57BL/6 background. Ap2αCre mice (Macatee et al., 2003) were
obtained from AnneMoon, University of Utah School of Medicine, Salt
Lake City, Utah, USA and maintained on a C57BL/6 background.
Genotyping of embryos was carried out on yolk sac or tail tip genomic
DNA as previously described (Ishibashi et al., 1995; Lindsay et al.,
1999, 2001). The Hes1 conditional allele was obtained from R.
Kageyama (Kita et al., 2007), and the ROSAR26R reporter originated
in the Soriano lab (Soriano, 1999). Mouse work was carried out in
accordance with British Home Ofﬁce regulations.
CMFDG labelling of a single cell suspension
E9.5 embryos were dissected out in DMEM+25 mM HEPES con-
taining 10% FCS. The embryos were staged by somite counting and
Df1/Tbx1lacZ embryoswere separated fromDf1/+, Tbx1+/lacZ andwild
type embryos. CMFDG loading was carried out using the Detectagene
green CMFDG lacZ gene expression kit (Molecular Probes). Following
three rinses in PBS, embryos were incubated in 0.25% trypsin (Gibco)
in PBS for approximately 30 min during which the embryos were
dissociated into a single cell suspension by trituration. The single cell
suspension was spun down at 300 x g for 3 min and resuspended in
pre-warmed (10 min at 37 °C) 50 μMCMDFG, 200 μMverapamil in 5%
FCS/DMEM + 25 mM HEPES and incubated for 30 min at 37 °C,
5% CO2. Following incubation, the cells were placed on ice and diluted
to approximately 1–3 million cells/mL with 5%FCS/DMEM + 25 mM
hepes. 1 mM PETG was added to stop the reaction and 1.5 μM
propidium iodide (PI) was added to identify dead cells. Cells were
ﬂow-sorted as soon as possible.
FACS analysis
Single cell suspensions were sorted using the Beckman Coulter
Epics Altra cell sorter (High Wycombe) and analysed using the Expo2
software (Beckman Coulter) or using the MoFlo cell sorter (Dakocy-
tomation, Fort Collins, Colorado) and analysed using the Summit
v4.11 software (Dakocytomation). Cells were gated on the basis of
forward scatter and side scatter characteristics to exclude debris. PI
was used as a viability stain to exclude all dead cells. Cells which were
ﬂuorescent for FDG above background were collected into 10%FCS/
DMEM + 25 mM HEPES and placed on ice. At least 50000 events
were acquired for analysis. Sorted cells were immediately spun down
at 300×g for 4 min and resuspended in Trizol (Gibco BRL) for RNA
extraction.
RT-PCR
FollowingRNA extraction, cDNAwas synthesized using Superscript
Reverse Transcriptase II (Invitrogen). Primers used were as follows:
Tbx1-wt, Tbx1ex4-F 5′-TTTGTGCCCGTAGATGACAA-3′ and Tbx1ex6-R
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CACATGCTTTACAT-3′ and IreslacZ-R 5′-GTTTTCCCAGTCACGACGTT-3′.
Microarray
Microarray hybridisation
Six Df1/Tbx1lacZ samples and six Tbx1+/lacZ samples were hybri-
dised onto MOE430 v2 oligonucleotide array chips (Affymetrix)
consisting of over 45000 probe sets representing over 34000 mouse
genes. Puriﬁed, biotin-UTP labelled cRNA was fragmented and
hybridised onto MOE430 v2 microarray chips according to Affymetrix
protocols and this was carried out by the ICH Gene Microarray Centre
(London UK). Arrays were scanned using the Affymetrix GeneChip
Scanner and array imageswere captured using theMicroarrayAnalysis
Suite v5 software package (MAS, Affymetrix). The report ﬁles were
examined to establish quality of the hybridisation.
Genespring analysis
Genespring software version 4.2.1 (Silicon Genetics) was used for
the comparison of Df1/Tbx1lacZ and Tbx1+/lacZ microarrays. Per chip
normalisation used the 50th percentile of all measurements as a
positive control for each sample. Measurements for each gene were
divided by this synthetic positive control. The bottom tenth percentile
was used as a test for correct background subtraction. Per gene nor-
malisation was then carried out, for which all Tbx1+/lacZ samples were
normalised to 1 and all Df1/Tbx1lacZ samples were normalised to the
Tbx1+/lacZ samples. The data from the mouse MOE430 v.2 microarray
chips was then ﬁltered to exclude genes with signals below the raw
value of 22. Seventeen out of twenty Df1 genes represented on the
chip were expressed above threshold levels. Iterative analyses were
then carried out on the normalised data to determine the appropriate
ﬁlters to apply in order to successfully identify the hemizygously-
expressed Df1 genes. Gene lists were statistically analysed using the
non-parametric t-test (Wilcoxon–Mann–Whitney/Kruskal–Wallis
test) with a p-value cutoff of 0.05 and the Benjamini and Hochberg
false discovery rate multiple testing correction was applied. Fourteen
out of 17 Df1 genes were downregulated to 0.83 in 5 out of 6 chips
hybridised with the Df1/Tbx1lacZ target under these conditions.
Quantitative real-time PCR
LacZ-expressing cells fromapool of at least 10 E9.5Df1/Tbx1+/− and
Tbx1+/− embryos were labelled using the CMFDG labelling kit
(Molecular Probes) and collected by FACS. RNA was isolated using
Trizol (Gibco BRL) and ampliﬁed by PCR-based ampliﬁcation using the
Microarray Target Ampliﬁcation kit (Roche). Quantitative real-time PCR
was carried out on the ABI PRISM 7000 Sequence Detection System
(Applied Biosystems). All reactions were performed in triplicate using
SYBR green (Qiagen) under the following PCR conditions: 95 °C for
15 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min and
expression values were obtained using the DART-PCR analysis excel
software which takes into account the ampliﬁcation efﬁciency of each
gene to obtain relative quantities (Peirson et al., 2003) or by using the
ΔΔCt method (Yuan et al., 2008). The qRT-PCR primers used can be
found in the supplementary data (Supplementary Table 3).
Mouse embryo analysis
In situ hybridization was performed according to previously
publishedmethods (Wilkinson, 1992).Hes1, Fgf8, Fgf10 and Etv4 probes
were generated from cDNA plasmid clones. β-galactosidase activitywas
detected in embryos ﬁxed in formaldehyde using X-gal (Promega)
following standard procedures. Indian Ink (Pelikan) was injected into
the outﬂow tract or aorta of embryos using a microinjection needle to
visualise thepharyngeal archarteries or great vessels of theheart.Multi-
embryomagnetic resonance imaging (MRI)was carriedout asdescribedpreviously (Schneider et al., 2004) on embryos at E15.5. Following
ﬁxation, embryos were dehydrated and embedded in wax. Sections
were cut at 8–12 µm and some were counterstained using Eosin.
Parafﬁn or cryosections were used for immunoﬂuorescence, 8–10 µm
sections were stained using antibodies against Endomucin (Clone
V.7C7 1/50, Santa Cruz), smooth muscle α-actin (Clone 1A4 1/700,
Sigma), Hes1 (1/200, R. Kageyama), Tbx1 (1/100, Zymed, Invitrogen),
β-galactosidase (1/300, Cappel), Isl1 (1/100, DSHB clones 402D6 and
394D5), phospho-Histone H3 (1/400, Upstate), Ki67 (1/25, Dako) and
Caspase 3 (1/100, Cell Signaling). For analysis of cell death using a
Caspase 3 antibody, neural crest cells were detected as mesenchymal
cells negative for Isl1 or a β-galactosidase-encoding transgene
expressed in pharyngeal mesoderm. Proliferation and cell death assays
were carried out onHes1mutant embryos in a CD1mutant background.
Data were obtained from four or more sections per embryo for three
embryos per genotype. Equivalent cell numbers were scored in wild
type and mutant embryos. Statistical analyses were carried out using
Student's t-test. Dapi or Hoechst was used for counterstaining sections
and the preparations were observed using an ApoTome microscope
(Zeiss).
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